Related Experiment Video
Updated: Jul 1, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Updates on Non-Statin LDL-Lowering Therapy
Amer Abdulla1, Mostafa Shalaby2, Paul Kumfa2
1, 301 University Blvd., JSA 5.106G, Galveston, TX, 77555-0553, USA. ameabdul@utmb.edu.
Purpose Of Review:
There is ample evidence of the benefits and safety of low-density lipoprotein (LDL)-lowering therapies in the prevention of atherosclerotic cardiovascular disease. While statins remain the first-line agent for LDL reduction, several new therapies are now available. This narrative review provides an overview of currently available non-statin LDL-lowering agents, specifically mechanisms of action and data on efficacy and safety. It also discusses recommendations on their use in clinical practice.
Recent Findings:
Ezetimibe, PCSK9 inhibitors, and bempedoic acid have proven safe and efficacious in reducing cardiovascular events in large randomized controlled trials. Inclisiran is a promising agent that suppresses PCSK9 mRNA translation and is currently under investigation in a large clinical outcomes randomized controlled trial assessing its effect on clinical outcomes. Expert consensus advocates for lower LDL targets in higher risk patients and escalation to or a combination of non-statin therapies as needed to achieve these goals.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug Therapy
Antianxiety Medications
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Drugs: Classification based on Therapeutic Indications
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Heart Failure Drugs: Inotropic Agents

